Apollo Life Sciences Begins Tests of Oral TNF Blocker for Arthritis
Apollo Life Sciences has announced that it is beginning pre-clinical trials of a tablet TNF blocker for arthritis, using its own Oradel(TM) oral delivery system, in tandem with its own ALS-00T2 TNF blocker, which was developed especially for delivery in tablet form.
The trials extend two key Apollo platforms - the company's Oradel oral delivery technology and the ALS-00T2 TNF blocker, which has already proven effective at reducing inflammation in animal trials when injected or rubbed on the skin, and has completed Phase 1b clinical human trials for psoriasis, according to the company.
"We are now broadening Oradel technology from insulin to the larger market of anti-inflammatories. The TNF blocker development represents an extension of our oral delivery platform," said Dr Greg Russell-Jones, Apollo's Science Director. "Successful studies with the TNF blocker will pave the way for using Oradel technology with any of the current antibody therapy technologies on the market. In other words, antibodies used in medicine that today have to be injected will be able to be delivered in tablet form."
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents

Cellphone converts into powerful chemical detector - With only $50 worth of components, an ordinary cellphone transforms into a sophisticated scientific instrument, capable of identifying chemicals, drugs, and pathogens
